{
    "Rank": 991,
    "Study": {
        "ProtocolSection": {
            "IdentificationModule": {
                "NCTId": "NCT01205685",
                "OrgStudyIdInfo": {
                    "OrgStudyId": "VICC BRE 09112"
                },
                "Organization": {
                    "OrgFullName": "Vanderbilt-Ingram Cancer Center",
                    "OrgClass": "OTHER"
                },
                "BriefTitle": "Endocrine Therapy + OSI-906 With or Without Erlotinib for Hormone-Sensitive Metastatic Breast Cancer",
                "OfficialTitle": "A Phase II Trial of Endocrine Therapy in Combination With OSI-906 (an IGF-1R Inhibitor) and Erlotinib (Tarceva\u00ae, an EGFR Inhibitor) in Patients With Hormone-sensitive Metastatic Breast Cancer"
            },
            "StatusModule": {
                "StatusVerifiedDate": "August 2012",
                "OverallStatus": "Terminated",
                "WhyStopped": "PI closed study early, all patients experienced severe toxicities and progressed",
                "ExpandedAccessInfo": {
                    "HasExpandedAccess": "No"
                },
                "StartDateStruct": {
                    "StartDate": "May 2010"
                },
                "PrimaryCompletionDateStruct": {
                    "PrimaryCompletionDate": "July 2011",
                    "PrimaryCompletionDateType": "Actual"
                },
                "CompletionDateStruct": {
                    "CompletionDate": "July 2011",
                    "CompletionDateType": "Actual"
                },
                "StudyFirstSubmitDate": "September 17, 2010",
                "StudyFirstSubmitQCDate": "September 17, 2010",
                "StudyFirstPostDateStruct": {
                    "StudyFirstPostDate": "September 20, 2010",
                    "StudyFirstPostDateType": "Estimate"
                },
                "ResultsFirstSubmitDate": "June 7, 2012",
                "ResultsFirstSubmitQCDate": "August 10, 2012",
                "ResultsFirstPostDateStruct": {
                    "ResultsFirstPostDate": "September 11, 2012",
                    "ResultsFirstPostDateType": "Estimate"
                },
                "LastUpdateSubmitDate": "August 10, 2012",
                "LastUpdatePostDateStruct": {
                    "LastUpdatePostDate": "September 11, 2012",
                    "LastUpdatePostDateType": "Estimate"
                }
            },
            "SponsorCollaboratorsModule": {
                "ResponsibleParty": {
                    "ResponsiblePartyType": "Principal Investigator",
                    "ResponsiblePartyInvestigatorFullName": "Ingrid Mayer, MD",
                    "ResponsiblePartyInvestigatorTitle": "Assistant Professor of Medicine; Clinical Director, Breast Cancer Program; Medical Oncologist",
                    "ResponsiblePartyInvestigatorAffiliation": "Vanderbilt-Ingram Cancer Center"
                },
                "LeadSponsor": {
                    "LeadSponsorName": "Vanderbilt-Ingram Cancer Center",
                    "LeadSponsorClass": "OTHER"
                }
            },
            "OversightModule": {
                "OversightHasDMC": "Yes"
            },
            "DescriptionModule": {
                "BriefSummary": "Erlotinib attacks a part of cancer cells that helps them live and grow. Studies done in human beings show that this drug can make a difference in the way anti-estrogens work in hormone-sensitive breast cancers. OSI-906 attacks a different part of the cancer cell that helps them live and grow. Studies done in the laboratory show that OSI-906 can make a difference in the way anti-estrogens work in hormone-sensitive breast cancers.",
                "DetailedDescription": "The safety run component of this trial is to determine the safety profile of the OSI-906, erlotinib and anti-endocrine treatment combination. The phase II component evaluates the antitumor activity of the combination OSI-906, erlotinib and endocrine therapy."
            },
            "ConditionsModule": {
                "ConditionList": {
                    "Condition": [
                        "Hormone-sensitive Metastatic Breast Cancer"
                    ]
                }
            },
            "DesignModule": {
                "StudyType": "Interventional",
                "PhaseList": {
                    "Phase": [
                        "Phase 2"
                    ]
                },
                "DesignInfo": {
                    "DesignAllocation": "N/A",
                    "DesignInterventionModel": "Single Group Assignment",
                    "DesignPrimaryPurpose": "Treatment",
                    "DesignMaskingInfo": {
                        "DesignMasking": "None (Open Label)"
                    }
                },
                "EnrollmentInfo": {
                    "EnrollmentCount": "11",
                    "EnrollmentType": "Actual"
                }
            },
            "ArmsInterventionsModule": {
                "ArmGroupList": {
                    "ArmGroup": [
                        {
                            "ArmGroupLabel": "OSI-906 + Erlotinib + Letrozole + Goserelin",
                            "ArmGroupType": "Experimental",
                            "ArmGroupDescription": "OSI-906 in a pill form, by mouth, twice a day (12 hours a part)\nErlotinib in a pill form, by mouth, once a day\nLetrozole in a pill form, by mouth, once a day\nGoserelin, by injection once per month for women who are pre-menopausal",
                            "ArmGroupInterventionList": {
                                "ArmGroupInterventionName": [
                                    "Drug: OSI-906",
                                    "Drug: Erlotinib",
                                    "Drug: Letrozole",
                                    "Drug: Goserelin"
                                ]
                            }
                        }
                    ]
                },
                "InterventionList": {
                    "Intervention": [
                        {
                            "InterventionType": "Drug",
                            "InterventionName": "OSI-906",
                            "InterventionDescription": "In a pill form by mouth, twice a day (12 hours apart)\n\nDuring the safety run portion of the study\"\n\nDose level 2 = 150 mg twice a day\nDose level 1 = 100 mg twice a day\nDose level -1 = 100 mg twice a day\nDose level -2 = 100 mg twice a day",
                            "InterventionArmGroupLabelList": {
                                "InterventionArmGroupLabel": [
                                    "OSI-906 + Erlotinib + Letrozole + Goserelin"
                                ]
                            }
                        },
                        {
                            "InterventionType": "Drug",
                            "InterventionName": "Erlotinib",
                            "InterventionDescription": "During the safety run phase of the study:\n\nDose Level 2 = 100 mg/d\nDose Level 1 = 100 mg/d\nDose Level -1= 75 mg/d\nDose Level -2 = 50 mg/d",
                            "InterventionArmGroupLabelList": {
                                "InterventionArmGroupLabel": [
                                    "OSI-906 + Erlotinib + Letrozole + Goserelin"
                                ]
                            }
                        },
                        {
                            "InterventionType": "Drug",
                            "InterventionName": "Letrozole",
                            "InterventionDescription": "In a pill form, by mouth, once per day at 2.5 mg/d.",
                            "InterventionArmGroupLabelList": {
                                "InterventionArmGroupLabel": [
                                    "OSI-906 + Erlotinib + Letrozole + Goserelin"
                                ]
                            }
                        },
                        {
                            "InterventionType": "Drug",
                            "InterventionName": "Goserelin",
                            "InterventionDescription": "For pre-menopausal patients only. Given as an injection once a month at 3.6 mg/month.",
                            "InterventionArmGroupLabelList": {
                                "InterventionArmGroupLabel": [
                                    "OSI-906 + Erlotinib + Letrozole + Goserelin"
                                ]
                            }
                        }
                    ]
                }
            },
            "OutcomesModule": {
                "PrimaryOutcomeList": {
                    "PrimaryOutcome": [
                        {
                            "PrimaryOutcomeMeasure": "Anti-tumor Activity of OSI-906",
                            "PrimaryOutcomeDescription": "Time to progression measured in months from study entry to date of disease progression",
                            "PrimaryOutcomeTimeFrame": "From study entry to 6 months"
                        }
                    ]
                },
                "SecondaryOutcomeList": {
                    "SecondaryOutcome": [
                        {
                            "SecondaryOutcomeMeasure": "Safety Profile Based on Number of Patients With Each Worst-grade Toxicity",
                            "SecondaryOutcomeDescription": "According to National Cancer Institute Common Toxicity Criteria for Adverse Events with 1 = mild, 2 = moderate, 3 = severe, 4 = life threatening/disabling, and 5 = death.",
                            "SecondaryOutcomeTimeFrame": "Every 4 weeks up to 24 weeks"
                        },
                        {
                            "SecondaryOutcomeMeasure": "Number of Participants With Tumor Response Per RECIST",
                            "SecondaryOutcomeDescription": "Per RECIST criteria v. 1.1: measurable lesions: complete response (CR) disappearance of target lesions, partial response (PR) > 30% decrease in the sum of the longest diameter (LD) of target lesions, progressive disease (PD) > 20% increase in the sum of the LD of target lesions or appearance of new lesions, stable disease (SD) neither sufficient decrease nor increase of the sum of smallest sum of the LD of target lesions",
                            "SecondaryOutcomeTimeFrame": "Every 12 weeks to tumor progression"
                        },
                        {
                            "SecondaryOutcomeMeasure": "Correlative Studies",
                            "SecondaryOutcomeDescription": "Biomarkers associated with response to OSI-906 + Erlotinib + Letrozole + Goserelin",
                            "SecondaryOutcomeTimeFrame": "< or = to 2 weeks before initiation of Phase II study treatment period"
                        }
                    ]
                }
            },
            "EligibilityModule": {
                "EligibilityCriteria": "Inclusion Criteria:\n\nPatients must provide informed written consent.\nPatients must be \u226518 years of age.\nECOG performance status 0-1.\nPatients with clinical stage IV invasive mammary carcinoma, previously documented by histological analysis, which is ER-positive and/or PR-positive by immunohistochemistry (IHC), which had previous endocrine therapy in the metastatic setting or had metastatic recurrence within 6 months of adjuvant endocrine therapy. Patients may have either measurable or non-measurable disease, both are allowed.\nPatients whose breast cancers are also HER2-overexpressed (IHC 3+ or FISHpositive) need to have had previous treatment exposure to trastuzumab (Herceptin\u00ae)\nLife expectancy \u2265 6 months\n\nPatients must have adequate hematologic, hepatic, and renal function. All tests must be obtained less than 2 weeks from study entry. This includes:\n\nANC \u22651250/mm3\nPlatelet count \u2265100,000/mm3\nCreatinine \u22641.5X upper limits of normal\nBilirubin, SGOT, SGPT \u2264 1.5 X upper limits of normal if no liver metastasis present*\nBilirubin, SGOT, SGPT, alkaline phosphatase \u2264 3 X upper limits of normal if liver metastasis present* *for patients with Gilbert's syndrome, direct bilirubin will be measured instead of total bilirubin\nAble to swallow and retain oral medication.\nPre-menopausal patients must have a negative pregnancy test prior to participating in the study. Women of childbearing age and their male counter parts should use a barrier method of contraception during and for 3 months following protocol therapy.\n\nPost-menopausal female subjects should be defined prior to protocol enrollment by any of the following:\n\nSubjects at least 55 years of age;\n\nSubjects under 55 years of age and amenorrheic for at least 12 months or follicle-stimulating hormone (FSH) values \u226540 IU/L and estradiol levels\n\n\u226420 IU/L;\n\nPrior bilateral oophorectomy or prior radiation castration with amenorrhea for at least 6 months.\nPatients may receive concurrent radiation therapy to painful bone metastases or areas of impending bone fracture as long as radiation therapy is initiated prior to study entry. Patients who have received prior radiotherapy must have recovered from any toxicity induced by this treatment (toxicity grade \u2264 1).\nPatients must be disease-free of prior invasive cancers for > 5 years with the exception of basal or squamous cancer of the skin or cervical carcinoma in situ.\nSubjects must complete all screening assessments as outlined in the protocol.\nPatients must have available tissue (archived formalin-fixed paraffin embedded blocks (FFPB) or fresh frozen tissue from original diagnosis or metastatic setting)for correlative studies. Tissue needs to be sent to VUMC (see Appendix E) at the time of registration. Patients will not be able to start study drugs without tissue availability.\n\nExclusion Criteria:\n\nLocally recurrent resectable breast cancer.\nPregnant or lactating women.\nPatients must not have had > than 4 prior chemotherapy treatments in the metastatic setting. This restriction does not include endocrine therapies or single agent biologic therapies.\nUse of CYP3A4 and CYP1A2 modifiers or drugs that prolong QTcF with high risk for Torsade de Pointes (see Appendix A)\nAny kind of malabsorption syndrome significantly affecting gastrointestinal function.\nHistory of other malignancy within 5 years prior to enrollment. Subjects with a history of completely resected non-melanoma skin cancer or successfully treated in situ carcinomas are eligible.\nPatients with baseline QTcF> 450 msec\nPatients with diabetes, glucose > 160 mg/dL or receiving ongoing antihyperglycemic therapies\n\nUncontrolled intercurrent illness including, but not limited to:\n\nongoing or active infection requiring parenteral antibiotics\nimpairment of lung function (COPD > grade 2, lung conditions requiring oxygen therapy)\nsymptomatic congestive heart failure (class III or IV of the New York Heart Association classification for heart disease)\nunstable angina pectoris, angioplasty, stenting, or myocardial infarction within 6 months\nuncontrolled hypertension (systolic blood pressure >180 mm Hg or diastolic blood pressure >100 mm Hg, found on two consecutive measurements separated by a 1-week period despite adequate medical support)\nclinically significant cardiac arrhythmia (multifocal premature ventricular contractions, bigeminy, trigeminy, ventricular tachycardia that is symptomatic or requires treatment [National Cancer Institute -Common Terminology Criteria for Adverse Events, Version 4.0, grade 3]\npsychiatric illness/social situations that would compromise patient safety or limit compliance with study requirements including maintenance of a compliance/pill diary\nPatients with symptomatic brain metastases (patients with a history of brain metastases must be clinically stable for more than 3 weeks from completion of radiation treatment and not taking steroids or therapeutic anticonvulsants that are CYP3A4 modifiers)\nPatients with asymptomatic brain metastasis on prophylactic anticonvulsants that are CYP3A4 modifiers\nConcurrent anti-cancer therapy (chemotherapy, radiation therapy, surgery, immunotherapy, hormonal therapy, biologic therapy) other than the ones specified in the protocol. Patients must have discontinued the above cancer therapies for 1 week prior to the first dose of study medication, as well as recovered from toxicity (to \u2264 than grade 1, except for alopecia, neuropathy, and ANC, which should be \u2265 1250/mm3) induced by previous treatments. Any other investigational drugs should be discontinued 2 weeks prior to the first dose of study medication.\nPrior therapy with an IGF-1R inhibitor",
                "HealthyVolunteers": "No",
                "Gender": "All",
                "MinimumAge": "18 Years",
                "StdAgeList": {
                    "StdAge": [
                        "Adult",
                        "Older Adult"
                    ]
                }
            },
            "ContactsLocationsModule": {
                "OverallOfficialList": {
                    "OverallOfficial": [
                        {
                            "OverallOfficialName": "Ingrid Mayer, M.D.",
                            "OverallOfficialAffiliation": "Vanderbilt-Ingram Cancer Center",
                            "OverallOfficialRole": "Principal Investigator"
                        }
                    ]
                },
                "LocationList": {
                    "Location": [
                        {
                            "LocationFacility": "Vanderbilt-Ingram Oncology Cool Springs",
                            "LocationCity": "Franklin",
                            "LocationState": "Tennessee",
                            "LocationZip": "37067",
                            "LocationCountry": "United States"
                        },
                        {
                            "LocationFacility": "Vanderbilt One Hundre Oaks",
                            "LocationCity": "Nashville",
                            "LocationState": "Tennessee",
                            "LocationZip": "37204",
                            "LocationCountry": "United States"
                        },
                        {
                            "LocationFacility": "Vanderbilt-Ingram Cancer Center",
                            "LocationCity": "Nashville",
                            "LocationState": "Tennessee",
                            "LocationZip": "37232",
                            "LocationCountry": "United States"
                        }
                    ]
                }
            }
        },
        "ResultsSection": {
            "ParticipantFlowModule": {
                "FlowPreAssignmentDetails": "12 patients consented, one of which was determined to be ineligible.",
                "FlowRecruitmentDetails": "This study was conducted from May 2010 and closed early one year later, May 2011.",
                "FlowGroupList": {
                    "FlowGroup": [
                        {
                            "FlowGroupId": "FG000",
                            "FlowGroupTitle": "OSI-906 + Erlotinib + Letrozole + Goserelin",
                            "FlowGroupDescription": "OSI-906 in a pill form, by mouth, twice a day (12 hours a part)\nErlotinib in a pill form, by mouth, once a day\nLetrozole in a pill form, by mouth, once a day\nGoserelin, by injection once per month for women who are pre-menopausal"
                        }
                    ]
                },
                "FlowPeriodList": {
                    "FlowPeriod": [
                        {
                            "FlowPeriodTitle": "Overall Study",
                            "FlowMilestoneList": {
                                "FlowMilestone": [
                                    {
                                        "FlowMilestoneType": "STARTED",
                                        "FlowAchievementList": {
                                            "FlowAchievement": [
                                                {
                                                    "FlowAchievementGroupId": "FG000",
                                                    "FlowAchievementNumSubjects": "11"
                                                }
                                            ]
                                        }
                                    },
                                    {
                                        "FlowMilestoneType": "COMPLETED",
                                        "FlowAchievementList": {
                                            "FlowAchievement": [
                                                {
                                                    "FlowAchievementGroupId": "FG000",
                                                    "FlowAchievementNumSubjects": "0"
                                                }
                                            ]
                                        }
                                    },
                                    {
                                        "FlowMilestoneType": "NOT COMPLETED",
                                        "FlowAchievementList": {
                                            "FlowAchievement": [
                                                {
                                                    "FlowAchievementGroupId": "FG000",
                                                    "FlowAchievementNumSubjects": "11"
                                                }
                                            ]
                                        }
                                    }
                                ]
                            },
                            "FlowDropWithdrawList": {
                                "FlowDropWithdraw": [
                                    {
                                        "FlowDropWithdrawType": "Disease Progression",
                                        "FlowReasonList": {
                                            "FlowReason": [
                                                {
                                                    "FlowReasonGroupId": "FG000",
                                                    "FlowReasonNumSubjects": "10"
                                                }
                                            ]
                                        }
                                    },
                                    {
                                        "FlowDropWithdrawType": "Withdrawal by Subject",
                                        "FlowReasonList": {
                                            "FlowReason": [
                                                {
                                                    "FlowReasonGroupId": "FG000",
                                                    "FlowReasonNumSubjects": "1"
                                                }
                                            ]
                                        }
                                    }
                                ]
                            }
                        }
                    ]
                }
            },
            "BaselineCharacteristicsModule": {
                "BaselineGroupList": {
                    "BaselineGroup": [
                        {
                            "BaselineGroupId": "BG000",
                            "BaselineGroupTitle": "OSI-906 + Erlotinib + Letrozole + Goserelin",
                            "BaselineGroupDescription": "OSI-906 in a pill form, by mouth, twice a day (12 hours a part)\nErlotinib in a pill form, by mouth, once a day\nLetrozole in a pill form, by mouth, once a day\nGoserelin, by injection once per month for women who are pre-menopausal"
                        }
                    ]
                },
                "BaselineDenomList": {
                    "BaselineDenom": [
                        {
                            "BaselineDenomUnits": "Participants",
                            "BaselineDenomCountList": {
                                "BaselineDenomCount": [
                                    {
                                        "BaselineDenomCountGroupId": "BG000",
                                        "BaselineDenomCountValue": "11"
                                    }
                                ]
                            }
                        }
                    ]
                },
                "BaselineMeasureList": {
                    "BaselineMeasure": [
                        {
                            "BaselineMeasureTitle": "Age, Categorical",
                            "BaselineMeasureParamType": "Count of Participants",
                            "BaselineMeasureUnitOfMeasure": "Participants",
                            "BaselineClassList": {
                                "BaselineClass": [
                                    {
                                        "BaselineCategoryList": {
                                            "BaselineCategory": [
                                                {
                                                    "BaselineCategoryTitle": "<=18 years",
                                                    "BaselineMeasurementList": {
                                                        "BaselineMeasurement": [
                                                            {
                                                                "BaselineMeasurementGroupId": "BG000",
                                                                "BaselineMeasurementValue": "0"
                                                            }
                                                        ]
                                                    }
                                                },
                                                {
                                                    "BaselineCategoryTitle": "Between 18 and 65 years",
                                                    "BaselineMeasurementList": {
                                                        "BaselineMeasurement": [
                                                            {
                                                                "BaselineMeasurementGroupId": "BG000",
                                                                "BaselineMeasurementValue": "8"
                                                            }
                                                        ]
                                                    }
                                                },
                                                {
                                                    "BaselineCategoryTitle": ">=65 years",
                                                    "BaselineMeasurementList": {
                                                        "BaselineMeasurement": [
                                                            {
                                                                "BaselineMeasurementGroupId": "BG000",
                                                                "BaselineMeasurementValue": "3"
                                                            }
                                                        ]
                                                    }
                                                }
                                            ]
                                        }
                                    }
                                ]
                            }
                        },
                        {
                            "BaselineMeasureTitle": "Age Continuous",
                            "BaselineMeasureParamType": "Mean",
                            "BaselineMeasureDispersionType": "Standard Deviation",
                            "BaselineMeasureUnitOfMeasure": "years",
                            "BaselineClassList": {
                                "BaselineClass": [
                                    {
                                        "BaselineCategoryList": {
                                            "BaselineCategory": [
                                                {
                                                    "BaselineMeasurementList": {
                                                        "BaselineMeasurement": [
                                                            {
                                                                "BaselineMeasurementGroupId": "BG000",
                                                                "BaselineMeasurementValue": "59",
                                                                "BaselineMeasurementSpread": "1"
                                                            }
                                                        ]
                                                    }
                                                }
                                            ]
                                        }
                                    }
                                ]
                            }
                        },
                        {
                            "BaselineMeasureTitle": "Sex: Female, Male",
                            "BaselineMeasureParamType": "Count of Participants",
                            "BaselineMeasureUnitOfMeasure": "Participants",
                            "BaselineClassList": {
                                "BaselineClass": [
                                    {
                                        "BaselineCategoryList": {
                                            "BaselineCategory": [
                                                {
                                                    "BaselineCategoryTitle": "Female",
                                                    "BaselineMeasurementList": {
                                                        "BaselineMeasurement": [
                                                            {
                                                                "BaselineMeasurementGroupId": "BG000",
                                                                "BaselineMeasurementValue": "11"
                                                            }
                                                        ]
                                                    }
                                                },
                                                {
                                                    "BaselineCategoryTitle": "Male",
                                                    "BaselineMeasurementList": {
                                                        "BaselineMeasurement": [
                                                            {
                                                                "BaselineMeasurementGroupId": "BG000",
                                                                "BaselineMeasurementValue": "0"
                                                            }
                                                        ]
                                                    }
                                                }
                                            ]
                                        }
                                    }
                                ]
                            }
                        },
                        {
                            "BaselineMeasureTitle": "Region of Enrollment",
                            "BaselineMeasureParamType": "Number",
                            "BaselineMeasureUnitOfMeasure": "participants",
                            "BaselineClassList": {
                                "BaselineClass": [
                                    {
                                        "BaselineClassTitle": "United States",
                                        "BaselineCategoryList": {
                                            "BaselineCategory": [
                                                {
                                                    "BaselineMeasurementList": {
                                                        "BaselineMeasurement": [
                                                            {
                                                                "BaselineMeasurementGroupId": "BG000",
                                                                "BaselineMeasurementValue": "11"
                                                            }
                                                        ]
                                                    }
                                                }
                                            ]
                                        }
                                    }
                                ]
                            }
                        }
                    ]
                }
            },
            "OutcomeMeasuresModule": {
                "OutcomeMeasureList": {
                    "OutcomeMeasure": [
                        {
                            "OutcomeMeasureType": "Primary",
                            "OutcomeMeasureTitle": "Anti-tumor Activity of OSI-906",
                            "OutcomeMeasureDescription": "Time to progression measured in months from study entry to date of disease progression",
                            "OutcomeMeasurePopulationDescription": "Patients who received treatment and who were available for determination of disease progression. One patient withdrew after beginning of treatment and was not available for determination of the duration of disease progression.",
                            "OutcomeMeasureReportingStatus": "Posted",
                            "OutcomeMeasureParamType": "Median",
                            "OutcomeMeasureDispersionType": "Full Range",
                            "OutcomeMeasureUnitOfMeasure": "months",
                            "OutcomeMeasureTimeFrame": "From study entry to 6 months",
                            "OutcomeGroupList": {
                                "OutcomeGroup": [
                                    {
                                        "OutcomeGroupId": "OG000",
                                        "OutcomeGroupTitle": "OSI-906 + Erlotinib + Letrozole + Goserelin",
                                        "OutcomeGroupDescription": "OSI-906 in a pill form, by mouth, twice a day (12 hours a part)\nErlotinib in a pill form, by mouth, once a day\nLetrozole in a pill form, by mouth, once a day\nGoserelin, by injection once per month for women who are pre-menopausal"
                                    }
                                ]
                            },
                            "OutcomeDenomList": {
                                "OutcomeDenom": [
                                    {
                                        "OutcomeDenomUnits": "Participants",
                                        "OutcomeDenomCountList": {
                                            "OutcomeDenomCount": [
                                                {
                                                    "OutcomeDenomCountGroupId": "OG000",
                                                    "OutcomeDenomCountValue": "10"
                                                }
                                            ]
                                        }
                                    }
                                ]
                            },
                            "OutcomeClassList": {
                                "OutcomeClass": [
                                    {
                                        "OutcomeCategoryList": {
                                            "OutcomeCategory": [
                                                {
                                                    "OutcomeMeasurementList": {
                                                        "OutcomeMeasurement": [
                                                            {
                                                                "OutcomeMeasurementGroupId": "OG000",
                                                                "OutcomeMeasurementValue": "2",
                                                                "OutcomeMeasurementLowerLimit": "0",
                                                                "OutcomeMeasurementUpperLimit": "2"
                                                            }
                                                        ]
                                                    }
                                                }
                                            ]
                                        }
                                    }
                                ]
                            }
                        },
                        {
                            "OutcomeMeasureType": "Secondary",
                            "OutcomeMeasureTitle": "Safety Profile Based on Number of Patients With Each Worst-grade Toxicity",
                            "OutcomeMeasureDescription": "According to National Cancer Institute Common Toxicity Criteria for Adverse Events with 1 = mild, 2 = moderate, 3 = severe, 4 = life threatening/disabling, and 5 = death.",
                            "OutcomeMeasurePopulationDescription": "Patients who received treatment and experienced an adverse event.",
                            "OutcomeMeasureReportingStatus": "Posted",
                            "OutcomeMeasureParamType": "Number",
                            "OutcomeMeasureUnitOfMeasure": "participants",
                            "OutcomeMeasureTimeFrame": "Every 4 weeks up to 24 weeks",
                            "OutcomeGroupList": {
                                "OutcomeGroup": [
                                    {
                                        "OutcomeGroupId": "OG000",
                                        "OutcomeGroupTitle": "OSI-906 + Erlotinib + Letrozole + Goserelin",
                                        "OutcomeGroupDescription": "OSI-906 in a pill form, by mouth, twice a day (12 hours a part)\nErlotinib in a pill form, by mouth, once a day\nLetrozole in a pill form, by mouth, once a day\nGoserelin, by injection once per month for women who are pre-menopausal"
                                    }
                                ]
                            },
                            "OutcomeDenomList": {
                                "OutcomeDenom": [
                                    {
                                        "OutcomeDenomUnits": "Participants",
                                        "OutcomeDenomCountList": {
                                            "OutcomeDenomCount": [
                                                {
                                                    "OutcomeDenomCountGroupId": "OG000",
                                                    "OutcomeDenomCountValue": "11"
                                                }
                                            ]
                                        }
                                    }
                                ]
                            },
                            "OutcomeClassList": {
                                "OutcomeClass": [
                                    {
                                        "OutcomeClassTitle": "Patients with worst grade toxicity of 1",
                                        "OutcomeCategoryList": {
                                            "OutcomeCategory": [
                                                {
                                                    "OutcomeMeasurementList": {
                                                        "OutcomeMeasurement": [
                                                            {
                                                                "OutcomeMeasurementGroupId": "OG000",
                                                                "OutcomeMeasurementValue": "2"
                                                            }
                                                        ]
                                                    }
                                                }
                                            ]
                                        }
                                    },
                                    {
                                        "OutcomeClassTitle": "Patients with worst grade toxicity of 2",
                                        "OutcomeCategoryList": {
                                            "OutcomeCategory": [
                                                {
                                                    "OutcomeMeasurementList": {
                                                        "OutcomeMeasurement": [
                                                            {
                                                                "OutcomeMeasurementGroupId": "OG000",
                                                                "OutcomeMeasurementValue": "6"
                                                            }
                                                        ]
                                                    }
                                                }
                                            ]
                                        }
                                    },
                                    {
                                        "OutcomeClassTitle": "Patients with worst grade toxicity of 3",
                                        "OutcomeCategoryList": {
                                            "OutcomeCategory": [
                                                {
                                                    "OutcomeMeasurementList": {
                                                        "OutcomeMeasurement": [
                                                            {
                                                                "OutcomeMeasurementGroupId": "OG000",
                                                                "OutcomeMeasurementValue": "3"
                                                            }
                                                        ]
                                                    }
                                                }
                                            ]
                                        }
                                    },
                                    {
                                        "OutcomeClassTitle": "Patients with worst grade toxicity of 4",
                                        "OutcomeCategoryList": {
                                            "OutcomeCategory": [
                                                {
                                                    "OutcomeMeasurementList": {
                                                        "OutcomeMeasurement": [
                                                            {
                                                                "OutcomeMeasurementGroupId": "OG000",
                                                                "OutcomeMeasurementValue": "0"
                                                            }
                                                        ]
                                                    }
                                                }
                                            ]
                                        }
                                    },
                                    {
                                        "OutcomeClassTitle": "Patients with worst grade toxicity of 5",
                                        "OutcomeCategoryList": {
                                            "OutcomeCategory": [
                                                {
                                                    "OutcomeMeasurementList": {
                                                        "OutcomeMeasurement": [
                                                            {
                                                                "OutcomeMeasurementGroupId": "OG000",
                                                                "OutcomeMeasurementValue": "0"
                                                            }
                                                        ]
                                                    }
                                                }
                                            ]
                                        }
                                    }
                                ]
                            }
                        },
                        {
                            "OutcomeMeasureType": "Secondary",
                            "OutcomeMeasureTitle": "Number of Participants With Tumor Response Per RECIST",
                            "OutcomeMeasureDescription": "Per RECIST criteria v. 1.1: measurable lesions: complete response (CR) disappearance of target lesions, partial response (PR) > 30% decrease in the sum of the longest diameter (LD) of target lesions, progressive disease (PD) > 20% increase in the sum of the LD of target lesions or appearance of new lesions, stable disease (SD) neither sufficient decrease nor increase of the sum of smallest sum of the LD of target lesions",
                            "OutcomeMeasurePopulationDescription": "Patients who were available for measurement of tumor response.",
                            "OutcomeMeasureReportingStatus": "Posted",
                            "OutcomeMeasureParamType": "Number",
                            "OutcomeMeasureUnitOfMeasure": "participants",
                            "OutcomeMeasureTimeFrame": "Every 12 weeks to tumor progression",
                            "OutcomeGroupList": {
                                "OutcomeGroup": [
                                    {
                                        "OutcomeGroupId": "OG000",
                                        "OutcomeGroupTitle": "OSI-906 + Erlotinib + Letrozole + Goserelin",
                                        "OutcomeGroupDescription": "OSI-906 in a pill form, by mouth, twice a day (12 hours a part)\nErlotinib in a pill form, by mouth, once a day\nLetrozole in a pill form, by mouth, once a day\nGoserelin, by injection once per month for women who are pre-menopausal"
                                    }
                                ]
                            },
                            "OutcomeDenomList": {
                                "OutcomeDenom": [
                                    {
                                        "OutcomeDenomUnits": "Participants",
                                        "OutcomeDenomCountList": {
                                            "OutcomeDenomCount": [
                                                {
                                                    "OutcomeDenomCountGroupId": "OG000",
                                                    "OutcomeDenomCountValue": "10"
                                                }
                                            ]
                                        }
                                    }
                                ]
                            },
                            "OutcomeClassList": {
                                "OutcomeClass": [
                                    {
                                        "OutcomeClassTitle": "Complete Response",
                                        "OutcomeCategoryList": {
                                            "OutcomeCategory": [
                                                {
                                                    "OutcomeMeasurementList": {
                                                        "OutcomeMeasurement": [
                                                            {
                                                                "OutcomeMeasurementGroupId": "OG000",
                                                                "OutcomeMeasurementValue": "0"
                                                            }
                                                        ]
                                                    }
                                                }
                                            ]
                                        }
                                    },
                                    {
                                        "OutcomeClassTitle": "Partial Response",
                                        "OutcomeCategoryList": {
                                            "OutcomeCategory": [
                                                {
                                                    "OutcomeMeasurementList": {
                                                        "OutcomeMeasurement": [
                                                            {
                                                                "OutcomeMeasurementGroupId": "OG000",
                                                                "OutcomeMeasurementValue": "0"
                                                            }
                                                        ]
                                                    }
                                                }
                                            ]
                                        }
                                    },
                                    {
                                        "OutcomeClassTitle": "Stable Disease",
                                        "OutcomeCategoryList": {
                                            "OutcomeCategory": [
                                                {
                                                    "OutcomeMeasurementList": {
                                                        "OutcomeMeasurement": [
                                                            {
                                                                "OutcomeMeasurementGroupId": "OG000",
                                                                "OutcomeMeasurementValue": "0"
                                                            }
                                                        ]
                                                    }
                                                }
                                            ]
                                        }
                                    },
                                    {
                                        "OutcomeClassTitle": "Progressive disease",
                                        "OutcomeCategoryList": {
                                            "OutcomeCategory": [
                                                {
                                                    "OutcomeMeasurementList": {
                                                        "OutcomeMeasurement": [
                                                            {
                                                                "OutcomeMeasurementGroupId": "OG000",
                                                                "OutcomeMeasurementValue": "10"
                                                            }
                                                        ]
                                                    }
                                                }
                                            ]
                                        }
                                    }
                                ]
                            }
                        },
                        {
                            "OutcomeMeasureType": "Secondary",
                            "OutcomeMeasureTitle": "Correlative Studies",
                            "OutcomeMeasureDescription": "Biomarkers associated with response to OSI-906 + Erlotinib + Letrozole + Goserelin",
                            "OutcomeMeasurePopulationDescription": "No correlative studies were performed because the study did not move to the Phase II portion",
                            "OutcomeMeasureReportingStatus": "Posted",
                            "OutcomeMeasureTimeFrame": "< or = to 2 weeks before initiation of Phase II study treatment period",
                            "OutcomeGroupList": {
                                "OutcomeGroup": [
                                    {
                                        "OutcomeGroupId": "OG000",
                                        "OutcomeGroupTitle": "OSI-906 + Erlotinib + Letrozole + Goserelin",
                                        "OutcomeGroupDescription": "OSI-906 in a pill form, by mouth, twice a day (12 hours a part)\nErlotinib in a pill form, by mouth, once a day\nLetrozole in a pill form, by mouth, once a day\nGoserelin, by injection once per month for women who are pre-menopausal"
                                    }
                                ]
                            },
                            "OutcomeDenomList": {
                                "OutcomeDenom": [
                                    {
                                        "OutcomeDenomUnits": "Participants",
                                        "OutcomeDenomCountList": {
                                            "OutcomeDenomCount": [
                                                {
                                                    "OutcomeDenomCountGroupId": "OG000",
                                                    "OutcomeDenomCountValue": "0"
                                                }
                                            ]
                                        }
                                    }
                                ]
                            }
                        }
                    ]
                }
            },
            "AdverseEventsModule": {
                "EventsFrequencyThreshold": "5",
                "EventGroupList": {
                    "EventGroup": [
                        {
                            "EventGroupId": "EG000",
                            "EventGroupTitle": "OSI-906 + Erlotinib + Letrozole + Goserelin",
                            "EventGroupDescription": "OSI-906 in a pill form, by mouth, twice a day (12 hours a part)\nErlotinib in a pill form, by mouth, once a day\nLetrozole in a pill form, by mouth, once a day\nGoserelin, by injection once per month for women who are pre-menopausal",
                            "EventGroupSeriousNumAffected": "2",
                            "EventGroupSeriousNumAtRisk": "11",
                            "EventGroupOtherNumAffected": "11",
                            "EventGroupOtherNumAtRisk": "11"
                        }
                    ]
                },
                "SeriousEventList": {
                    "SeriousEvent": [
                        {
                            "SeriousEventTerm": "Acute kidney injury",
                            "SeriousEventOrganSystem": "Renal and urinary disorders",
                            "SeriousEventStatsList": {
                                "SeriousEventStats": [
                                    {
                                        "SeriousEventStatsGroupId": "EG000",
                                        "SeriousEventStatsNumEvents": "1",
                                        "SeriousEventStatsNumAffected": "1",
                                        "SeriousEventStatsNumAtRisk": "11"
                                    }
                                ]
                            }
                        },
                        {
                            "SeriousEventTerm": "Hypercalcemia",
                            "SeriousEventOrganSystem": "Metabolism and nutrition disorders",
                            "SeriousEventStatsList": {
                                "SeriousEventStats": [
                                    {
                                        "SeriousEventStatsGroupId": "EG000",
                                        "SeriousEventStatsNumEvents": "2",
                                        "SeriousEventStatsNumAffected": "2",
                                        "SeriousEventStatsNumAtRisk": "11"
                                    }
                                ]
                            }
                        },
                        {
                            "SeriousEventTerm": "Fatigue",
                            "SeriousEventOrganSystem": "General disorders",
                            "SeriousEventStatsList": {
                                "SeriousEventStats": [
                                    {
                                        "SeriousEventStatsGroupId": "EG000",
                                        "SeriousEventStatsNumEvents": "1",
                                        "SeriousEventStatsNumAffected": "1",
                                        "SeriousEventStatsNumAtRisk": "11"
                                    }
                                ]
                            }
                        }
                    ]
                },
                "OtherEventList": {
                    "OtherEvent": [
                        {
                            "OtherEventTerm": "alanine aminotransferase increased",
                            "OtherEventOrganSystem": "Investigations",
                            "OtherEventAssessmentType": "Systematic Assessment",
                            "OtherEventStatsList": {
                                "OtherEventStats": [
                                    {
                                        "OtherEventStatsGroupId": "EG000",
                                        "OtherEventStatsNumEvents": "7",
                                        "OtherEventStatsNumAffected": "4",
                                        "OtherEventStatsNumAtRisk": "11"
                                    }
                                ]
                            }
                        },
                        {
                            "OtherEventTerm": "alkaline phosphatase increased",
                            "OtherEventOrganSystem": "Investigations",
                            "OtherEventAssessmentType": "Systematic Assessment",
                            "OtherEventStatsList": {
                                "OtherEventStats": [
                                    {
                                        "OtherEventStatsGroupId": "EG000",
                                        "OtherEventStatsNumEvents": "4",
                                        "OtherEventStatsNumAffected": "3",
                                        "OtherEventStatsNumAtRisk": "11"
                                    }
                                ]
                            }
                        },
                        {
                            "OtherEventTerm": "anemia",
                            "OtherEventOrganSystem": "Blood and lymphatic system disorders",
                            "OtherEventAssessmentType": "Systematic Assessment",
                            "OtherEventStatsList": {
                                "OtherEventStats": [
                                    {
                                        "OtherEventStatsGroupId": "EG000",
                                        "OtherEventStatsNumEvents": "5",
                                        "OtherEventStatsNumAffected": "3",
                                        "OtherEventStatsNumAtRisk": "11"
                                    }
                                ]
                            }
                        },
                        {
                            "OtherEventTerm": "anorexia",
                            "OtherEventOrganSystem": "Metabolism and nutrition disorders",
                            "OtherEventAssessmentType": "Non-systematic Assessment",
                            "OtherEventStatsList": {
                                "OtherEventStats": [
                                    {
                                        "OtherEventStatsGroupId": "EG000",
                                        "OtherEventStatsNumEvents": "1",
                                        "OtherEventStatsNumAffected": "1",
                                        "OtherEventStatsNumAtRisk": "11"
                                    }
                                ]
                            }
                        },
                        {
                            "OtherEventTerm": "aspartate aminotransferase increased",
                            "OtherEventOrganSystem": "Investigations",
                            "OtherEventAssessmentType": "Systematic Assessment",
                            "OtherEventStatsList": {
                                "OtherEventStats": [
                                    {
                                        "OtherEventStatsGroupId": "EG000",
                                        "OtherEventStatsNumEvents": "5",
                                        "OtherEventStatsNumAffected": "5",
                                        "OtherEventStatsNumAtRisk": "11"
                                    }
                                ]
                            }
                        },
                        {
                            "OtherEventTerm": "back pain",
                            "OtherEventOrganSystem": "Musculoskeletal and connective tissue disorders",
                            "OtherEventAssessmentType": "Non-systematic Assessment",
                            "OtherEventStatsList": {
                                "OtherEventStats": [
                                    {
                                        "OtherEventStatsGroupId": "EG000",
                                        "OtherEventStatsNumEvents": "1",
                                        "OtherEventStatsNumAffected": "1",
                                        "OtherEventStatsNumAtRisk": "11"
                                    }
                                ]
                            }
                        },
                        {
                            "OtherEventTerm": "bladder spasm",
                            "OtherEventOrganSystem": "Renal and urinary disorders",
                            "OtherEventAssessmentType": "Non-systematic Assessment",
                            "OtherEventStatsList": {
                                "OtherEventStats": [
                                    {
                                        "OtherEventStatsGroupId": "EG000",
                                        "OtherEventStatsNumEvents": "1",
                                        "OtherEventStatsNumAffected": "1",
                                        "OtherEventStatsNumAtRisk": "11"
                                    }
                                ]
                            }
                        },
                        {
                            "OtherEventTerm": "creatinine increased",
                            "OtherEventOrganSystem": "Investigations",
                            "OtherEventAssessmentType": "Systematic Assessment",
                            "OtherEventStatsList": {
                                "OtherEventStats": [
                                    {
                                        "OtherEventStatsGroupId": "EG000",
                                        "OtherEventStatsNumEvents": "3",
                                        "OtherEventStatsNumAffected": "1",
                                        "OtherEventStatsNumAtRisk": "11"
                                    }
                                ]
                            }
                        },
                        {
                            "OtherEventTerm": "depression",
                            "OtherEventOrganSystem": "Psychiatric disorders",
                            "OtherEventAssessmentType": "Non-systematic Assessment",
                            "OtherEventStatsList": {
                                "OtherEventStats": [
                                    {
                                        "OtherEventStatsGroupId": "EG000",
                                        "OtherEventStatsNumEvents": "2",
                                        "OtherEventStatsNumAffected": "2",
                                        "OtherEventStatsNumAtRisk": "11"
                                    }
                                ]
                            }
                        },
                        {
                            "OtherEventTerm": "diarrhea",
                            "OtherEventOrganSystem": "Gastrointestinal disorders",
                            "OtherEventAssessmentType": "Non-systematic Assessment",
                            "OtherEventStatsList": {
                                "OtherEventStats": [
                                    {
                                        "OtherEventStatsGroupId": "EG000",
                                        "OtherEventStatsNumEvents": "4",
                                        "OtherEventStatsNumAffected": "4",
                                        "OtherEventStatsNumAtRisk": "11"
                                    }
                                ]
                            }
                        },
                        {
                            "OtherEventTerm": "dizziness",
                            "OtherEventOrganSystem": "Nervous system disorders",
                            "OtherEventAssessmentType": "Non-systematic Assessment",
                            "OtherEventStatsList": {
                                "OtherEventStats": [
                                    {
                                        "OtherEventStatsGroupId": "EG000",
                                        "OtherEventStatsNumEvents": "1",
                                        "OtherEventStatsNumAffected": "1",
                                        "OtherEventStatsNumAtRisk": "11"
                                    }
                                ]
                            }
                        },
                        {
                            "OtherEventTerm": "dry eye",
                            "OtherEventOrganSystem": "Eye disorders",
                            "OtherEventAssessmentType": "Non-systematic Assessment",
                            "OtherEventStatsList": {
                                "OtherEventStats": [
                                    {
                                        "OtherEventStatsGroupId": "EG000",
                                        "OtherEventStatsNumEvents": "1",
                                        "OtherEventStatsNumAffected": "1",
                                        "OtherEventStatsNumAtRisk": "11"
                                    }
                                ]
                            }
                        },
                        {
                            "OtherEventTerm": "dry mouth",
                            "OtherEventOrganSystem": "Gastrointestinal disorders",
                            "OtherEventAssessmentType": "Non-systematic Assessment",
                            "OtherEventStatsList": {
                                "OtherEventStats": [
                                    {
                                        "OtherEventStatsGroupId": "EG000",
                                        "OtherEventStatsNumEvents": "1",
                                        "OtherEventStatsNumAffected": "1",
                                        "OtherEventStatsNumAtRisk": "11"
                                    }
                                ]
                            }
                        },
                        {
                            "OtherEventTerm": "dry skin",
                            "OtherEventOrganSystem": "Skin and subcutaneous tissue disorders",
                            "OtherEventAssessmentType": "Non-systematic Assessment",
                            "OtherEventStatsList": {
                                "OtherEventStats": [
                                    {
                                        "OtherEventStatsGroupId": "EG000",
                                        "OtherEventStatsNumEvents": "2",
                                        "OtherEventStatsNumAffected": "2",
                                        "OtherEventStatsNumAtRisk": "11"
                                    }
                                ]
                            }
                        },
                        {
                            "OtherEventTerm": "electrocardiagram QT interval prolonged",
                            "OtherEventOrganSystem": "Cardiac disorders",
                            "OtherEventAssessmentType": "Systematic Assessment",
                            "OtherEventStatsList": {
                                "OtherEventStats": [
                                    {
                                        "OtherEventStatsGroupId": "EG000",
                                        "OtherEventStatsNumEvents": "2",
                                        "OtherEventStatsNumAffected": "2",
                                        "OtherEventStatsNumAtRisk": "11"
                                    }
                                ]
                            }
                        },
                        {
                            "OtherEventTerm": "epistaxis",
                            "OtherEventOrganSystem": "Respiratory, thoracic and mediastinal disorders",
                            "OtherEventAssessmentType": "Non-systematic Assessment",
                            "OtherEventStatsList": {
                                "OtherEventStats": [
                                    {
                                        "OtherEventStatsGroupId": "EG000",
                                        "OtherEventStatsNumEvents": "2",
                                        "OtherEventStatsNumAffected": "1",
                                        "OtherEventStatsNumAtRisk": "11"
                                    }
                                ]
                            }
                        },
                        {
                            "OtherEventTerm": "eye disorders",
                            "OtherEventOrganSystem": "Eye disorders",
                            "OtherEventAssessmentType": "Non-systematic Assessment",
                            "OtherEventStatsList": {
                                "OtherEventStats": [
                                    {
                                        "OtherEventStatsGroupId": "EG000",
                                        "OtherEventStatsNumEvents": "2",
                                        "OtherEventStatsNumAffected": "1",
                                        "OtherEventStatsNumAtRisk": "11"
                                    }
                                ]
                            }
                        },
                        {
                            "OtherEventTerm": "hypercalcemia",
                            "OtherEventOrganSystem": "Metabolism and nutrition disorders",
                            "OtherEventAssessmentType": "Systematic Assessment",
                            "OtherEventStatsList": {
                                "OtherEventStats": [
                                    {
                                        "OtherEventStatsGroupId": "EG000",
                                        "OtherEventStatsNumEvents": "5",
                                        "OtherEventStatsNumAffected": "2",
                                        "OtherEventStatsNumAtRisk": "11"
                                    }
                                ]
                            }
                        },
                        {
                            "OtherEventTerm": "hyperglycemia",
                            "OtherEventOrganSystem": "Metabolism and nutrition disorders",
                            "OtherEventAssessmentType": "Systematic Assessment",
                            "OtherEventStatsList": {
                                "OtherEventStats": [
                                    {
                                        "OtherEventStatsGroupId": "EG000",
                                        "OtherEventStatsNumEvents": "5",
                                        "OtherEventStatsNumAffected": "5",
                                        "OtherEventStatsNumAtRisk": "11"
                                    }
                                ]
                            }
                        },
                        {
                            "OtherEventTerm": "hypocalcemia",
                            "OtherEventOrganSystem": "Metabolism and nutrition disorders",
                            "OtherEventAssessmentType": "Systematic Assessment",
                            "OtherEventStatsList": {
                                "OtherEventStats": [
                                    {
                                        "OtherEventStatsGroupId": "EG000",
                                        "OtherEventStatsNumEvents": "2",
                                        "OtherEventStatsNumAffected": "2",
                                        "OtherEventStatsNumAtRisk": "11"
                                    }
                                ]
                            }
                        },
                        {
                            "OtherEventTerm": "hypoglycemia",
                            "OtherEventOrganSystem": "Metabolism and nutrition disorders",
                            "OtherEventAssessmentType": "Systematic Assessment",
                            "OtherEventStatsList": {
                                "OtherEventStats": [
                                    {
                                        "OtherEventStatsGroupId": "EG000",
                                        "OtherEventStatsNumEvents": "1",
                                        "OtherEventStatsNumAffected": "1",
                                        "OtherEventStatsNumAtRisk": "11"
                                    }
                                ]
                            }
                        },
                        {
                            "OtherEventTerm": "hypokalemia",
                            "OtherEventOrganSystem": "Metabolism and nutrition disorders",
                            "OtherEventAssessmentType": "Systematic Assessment",
                            "OtherEventStatsList": {
                                "OtherEventStats": [
                                    {
                                        "OtherEventStatsGroupId": "EG000",
                                        "OtherEventStatsNumEvents": "5",
                                        "OtherEventStatsNumAffected": "4",
                                        "OtherEventStatsNumAtRisk": "11"
                                    }
                                ]
                            }
                        },
                        {
                            "OtherEventTerm": "hyponatremia",
                            "OtherEventOrganSystem": "Metabolism and nutrition disorders",
                            "OtherEventAssessmentType": "Systematic Assessment",
                            "OtherEventStatsList": {
                                "OtherEventStats": [
                                    {
                                        "OtherEventStatsGroupId": "EG000",
                                        "OtherEventStatsNumEvents": "4",
                                        "OtherEventStatsNumAffected": "3",
                                        "OtherEventStatsNumAtRisk": "11"
                                    }
                                ]
                            }
                        },
                        {
                            "OtherEventTerm": "insomnia",
                            "OtherEventOrganSystem": "Psychiatric disorders",
                            "OtherEventAssessmentType": "Non-systematic Assessment",
                            "OtherEventStatsList": {
                                "OtherEventStats": [
                                    {
                                        "OtherEventStatsGroupId": "EG000",
                                        "OtherEventStatsNumEvents": "1",
                                        "OtherEventStatsNumAffected": "1",
                                        "OtherEventStatsNumAtRisk": "11"
                                    }
                                ]
                            }
                        },
                        {
                            "OtherEventTerm": "leukocytosis",
                            "OtherEventOrganSystem": "Blood and lymphatic system disorders",
                            "OtherEventAssessmentType": "Systematic Assessment",
                            "OtherEventStatsList": {
                                "OtherEventStats": [
                                    {
                                        "OtherEventStatsGroupId": "EG000",
                                        "OtherEventStatsNumEvents": "11",
                                        "OtherEventStatsNumAffected": "1",
                                        "OtherEventStatsNumAtRisk": "11"
                                    }
                                ]
                            }
                        },
                        {
                            "OtherEventTerm": "mucositis oral",
                            "OtherEventOrganSystem": "Gastrointestinal disorders",
                            "OtherEventAssessmentType": "Non-systematic Assessment",
                            "OtherEventStatsList": {
                                "OtherEventStats": [
                                    {
                                        "OtherEventStatsGroupId": "EG000",
                                        "OtherEventStatsNumEvents": "2",
                                        "OtherEventStatsNumAffected": "2",
                                        "OtherEventStatsNumAtRisk": "11"
                                    }
                                ]
                            }
                        },
                        {
                            "OtherEventTerm": "nausea",
                            "OtherEventOrganSystem": "Gastrointestinal disorders",
                            "OtherEventAssessmentType": "Non-systematic Assessment",
                            "OtherEventStatsList": {
                                "OtherEventStats": [
                                    {
                                        "OtherEventStatsGroupId": "EG000",
                                        "OtherEventStatsNumEvents": "2",
                                        "OtherEventStatsNumAffected": "2",
                                        "OtherEventStatsNumAtRisk": "11"
                                    }
                                ]
                            }
                        },
                        {
                            "OtherEventTerm": "non-cardiac chest pain",
                            "OtherEventOrganSystem": "Musculoskeletal and connective tissue disorders",
                            "OtherEventAssessmentType": "Non-systematic Assessment",
                            "OtherEventStatsList": {
                                "OtherEventStats": [
                                    {
                                        "OtherEventStatsGroupId": "EG000",
                                        "OtherEventStatsNumEvents": "1",
                                        "OtherEventStatsNumAffected": "1",
                                        "OtherEventStatsNumAtRisk": "11"
                                    }
                                ]
                            }
                        },
                        {
                            "OtherEventTerm": "pain",
                            "OtherEventOrganSystem": "General disorders",
                            "OtherEventAssessmentType": "Non-systematic Assessment",
                            "OtherEventStatsList": {
                                "OtherEventStats": [
                                    {
                                        "OtherEventStatsGroupId": "EG000",
                                        "OtherEventStatsNumEvents": "1",
                                        "OtherEventStatsNumAffected": "1",
                                        "OtherEventStatsNumAtRisk": "11"
                                    }
                                ]
                            }
                        },
                        {
                            "OtherEventTerm": "rash acneiform",
                            "OtherEventOrganSystem": "Skin and subcutaneous tissue disorders",
                            "OtherEventAssessmentType": "Non-systematic Assessment",
                            "OtherEventStatsList": {
                                "OtherEventStats": [
                                    {
                                        "OtherEventStatsGroupId": "EG000",
                                        "OtherEventStatsNumEvents": "8",
                                        "OtherEventStatsNumAffected": "7",
                                        "OtherEventStatsNumAtRisk": "11"
                                    }
                                ]
                            }
                        },
                        {
                            "OtherEventTerm": "rash macro-papular",
                            "OtherEventOrganSystem": "Skin and subcutaneous tissue disorders",
                            "OtherEventAssessmentType": "Non-systematic Assessment",
                            "OtherEventStatsList": {
                                "OtherEventStats": [
                                    {
                                        "OtherEventStatsGroupId": "EG000",
                                        "OtherEventStatsNumEvents": "1",
                                        "OtherEventStatsNumAffected": "1",
                                        "OtherEventStatsNumAtRisk": "11"
                                    }
                                ]
                            }
                        },
                        {
                            "OtherEventTerm": "skin and subcutaneous tissue disorders Other",
                            "OtherEventOrganSystem": "Skin and subcutaneous tissue disorders",
                            "OtherEventAssessmentType": "Non-systematic Assessment",
                            "OtherEventStatsList": {
                                "OtherEventStats": [
                                    {
                                        "OtherEventStatsGroupId": "EG000",
                                        "OtherEventStatsNumEvents": "1",
                                        "OtherEventStatsNumAffected": "1",
                                        "OtherEventStatsNumAtRisk": "11"
                                    }
                                ]
                            }
                        },
                        {
                            "OtherEventTerm": "upper respiratory infection",
                            "OtherEventOrganSystem": "Respiratory, thoracic and mediastinal disorders",
                            "OtherEventAssessmentType": "Systematic Assessment",
                            "OtherEventStatsList": {
                                "OtherEventStats": [
                                    {
                                        "OtherEventStatsGroupId": "EG000",
                                        "OtherEventStatsNumEvents": "1",
                                        "OtherEventStatsNumAffected": "1",
                                        "OtherEventStatsNumAtRisk": "11"
                                    }
                                ]
                            }
                        },
                        {
                            "OtherEventTerm": "urinary incontinence",
                            "OtherEventOrganSystem": "Renal and urinary disorders",
                            "OtherEventAssessmentType": "Systematic Assessment",
                            "OtherEventStatsList": {
                                "OtherEventStats": [
                                    {
                                        "OtherEventStatsGroupId": "EG000",
                                        "OtherEventStatsNumEvents": "1",
                                        "OtherEventStatsNumAffected": "1",
                                        "OtherEventStatsNumAtRisk": "11"
                                    }
                                ]
                            }
                        },
                        {
                            "OtherEventTerm": "flu-like symptoms",
                            "OtherEventOrganSystem": "General disorders",
                            "OtherEventAssessmentType": "Non-systematic Assessment",
                            "OtherEventStatsList": {
                                "OtherEventStats": [
                                    {
                                        "OtherEventStatsGroupId": "EG000",
                                        "OtherEventStatsNumEvents": "1",
                                        "OtherEventStatsNumAffected": "1",
                                        "OtherEventStatsNumAtRisk": "11"
                                    }
                                ]
                            }
                        },
                        {
                            "OtherEventTerm": "fatigue",
                            "OtherEventOrganSystem": "General disorders",
                            "OtherEventAssessmentType": "Non-systematic Assessment",
                            "OtherEventStatsList": {
                                "OtherEventStats": [
                                    {
                                        "OtherEventStatsGroupId": "EG000",
                                        "OtherEventStatsNumEvents": "3",
                                        "OtherEventStatsNumAffected": "2",
                                        "OtherEventStatsNumAtRisk": "11"
                                    }
                                ]
                            }
                        },
                        {
                            "OtherEventTerm": "pruritis",
                            "OtherEventOrganSystem": "Skin and subcutaneous tissue disorders",
                            "OtherEventAssessmentType": "Non-systematic Assessment",
                            "OtherEventStatsList": {
                                "OtherEventStats": [
                                    {
                                        "OtherEventStatsGroupId": "EG000",
                                        "OtherEventStatsNumEvents": "1",
                                        "OtherEventStatsNumAffected": "1",
                                        "OtherEventStatsNumAtRisk": "11"
                                    }
                                ]
                            }
                        },
                        {
                            "OtherEventTerm": "gastrointestinal disorders Other",
                            "OtherEventOrganSystem": "Gastrointestinal disorders",
                            "OtherEventAssessmentType": "Non-systematic Assessment",
                            "OtherEventStatsList": {
                                "OtherEventStats": [
                                    {
                                        "OtherEventStatsGroupId": "EG000",
                                        "OtherEventStatsNumEvents": "1",
                                        "OtherEventStatsNumAffected": "1",
                                        "OtherEventStatsNumAtRisk": "11"
                                    }
                                ]
                            }
                        },
                        {
                            "OtherEventTerm": "general disorders and administrative site disorders-other",
                            "OtherEventOrganSystem": "General disorders",
                            "OtherEventStatsList": {
                                "OtherEventStats": [
                                    {
                                        "OtherEventStatsGroupId": "EG000",
                                        "OtherEventStatsNumEvents": "2",
                                        "OtherEventStatsNumAffected": "1",
                                        "OtherEventStatsNumAtRisk": "11"
                                    }
                                ]
                            }
                        },
                        {
                            "OtherEventTerm": "hypothyroidism",
                            "OtherEventOrganSystem": "Endocrine disorders",
                            "OtherEventStatsList": {
                                "OtherEventStats": [
                                    {
                                        "OtherEventStatsGroupId": "EG000",
                                        "OtherEventStatsNumEvents": "1",
                                        "OtherEventStatsNumAffected": "1",
                                        "OtherEventStatsNumAtRisk": "11"
                                    }
                                ]
                            }
                        },
                        {
                            "OtherEventTerm": "pain-bone",
                            "OtherEventOrganSystem": "Musculoskeletal and connective tissue disorders",
                            "OtherEventStatsList": {
                                "OtherEventStats": [
                                    {
                                        "OtherEventStatsGroupId": "EG000",
                                        "OtherEventStatsNumEvents": "1",
                                        "OtherEventStatsNumAffected": "1",
                                        "OtherEventStatsNumAtRisk": "11"
                                    }
                                ]
                            }
                        },
                        {
                            "OtherEventTerm": "flu-like symptoms",
                            "OtherEventOrganSystem": "General disorders",
                            "OtherEventStatsList": {
                                "OtherEventStats": [
                                    {
                                        "OtherEventStatsGroupId": "EG000",
                                        "OtherEventStatsNumEvents": "1",
                                        "OtherEventStatsNumAffected": "1",
                                        "OtherEventStatsNumAtRisk": "11"
                                    }
                                ]
                            }
                        },
                        {
                            "OtherEventTerm": "neutrophil count decreased",
                            "OtherEventOrganSystem": "Investigations",
                            "OtherEventStatsList": {
                                "OtherEventStats": [
                                    {
                                        "OtherEventStatsGroupId": "EG000",
                                        "OtherEventStatsNumEvents": "1",
                                        "OtherEventStatsNumAffected": "1",
                                        "OtherEventStatsNumAtRisk": "11"
                                    }
                                ]
                            }
                        },
                        {
                            "OtherEventTerm": "white blood cells decreased",
                            "OtherEventOrganSystem": "Investigations",
                            "OtherEventStatsList": {
                                "OtherEventStats": [
                                    {
                                        "OtherEventStatsGroupId": "EG000",
                                        "OtherEventStatsNumEvents": "1",
                                        "OtherEventStatsNumAffected": "1",
                                        "OtherEventStatsNumAtRisk": "11"
                                    }
                                ]
                            }
                        },
                        {
                            "OtherEventTerm": "leukocytosis",
                            "OtherEventOrganSystem": "Blood and lymphatic system disorders",
                            "OtherEventStatsList": {
                                "OtherEventStats": [
                                    {
                                        "OtherEventStatsGroupId": "EG000",
                                        "OtherEventStatsNumEvents": "1",
                                        "OtherEventStatsNumAffected": "1",
                                        "OtherEventStatsNumAtRisk": "11"
                                    }
                                ]
                            }
                        },
                        {
                            "OtherEventTerm": "acute kidney injury",
                            "OtherEventOrganSystem": "Renal and urinary disorders",
                            "OtherEventStatsList": {
                                "OtherEventStats": [
                                    {
                                        "OtherEventStatsGroupId": "EG000",
                                        "OtherEventStatsNumEvents": "1",
                                        "OtherEventStatsNumAffected": "1",
                                        "OtherEventStatsNumAtRisk": "11"
                                    }
                                ]
                            }
                        }
                    ]
                }
            },
            "MoreInfoModule": {
                "CertainAgreement": {
                    "AgreementPISponsorEmployee": "Yes"
                },
                "PointOfContact": {
                    "PointOfContactTitle": "Dr. Ingrid Mayer",
                    "PointOfContactOrganization": "Vanderbilt-Ingram Cancer Center",
                    "PointOfContactEMail": "ingrid.mayer@vanderbilt.edu",
                    "PointOfContactPhone": "615-936-2033"
                }
            }
        },
        "DerivedSection": {
            "MiscInfoModule": {
                "VersionHolder": "September 08, 2023"
            },
            "ConditionBrowseModule": {
                "ConditionMeshList": {
                    "ConditionMesh": [
                        {
                            "ConditionMeshId": "D000001943",
                            "ConditionMeshTerm": "Breast Neoplasms"
                        },
                        {
                            "ConditionMeshId": "D000006967",
                            "ConditionMeshTerm": "Hypersensitivity"
                        }
                    ]
                },
                "ConditionAncestorList": {
                    "ConditionAncestor": [
                        {
                            "ConditionAncestorId": "D000009371",
                            "ConditionAncestorTerm": "Neoplasms by Site"
                        },
                        {
                            "ConditionAncestorId": "D000009369",
                            "ConditionAncestorTerm": "Neoplasms"
                        },
                        {
                            "ConditionAncestorId": "D000001941",
                            "ConditionAncestorTerm": "Breast Diseases"
                        },
                        {
                            "ConditionAncestorId": "D000012871",
                            "ConditionAncestorTerm": "Skin Diseases"
                        },
                        {
                            "ConditionAncestorId": "D000007154",
                            "ConditionAncestorTerm": "Immune System Diseases"
                        }
                    ]
                },
                "ConditionBrowseLeafList": {
                    "ConditionBrowseLeaf": [
                        {
                            "ConditionBrowseLeafId": "M4910",
                            "ConditionBrowseLeafName": "Breast Neoplasms",
                            "ConditionBrowseLeafAsFound": "Breast Cancer",
                            "ConditionBrowseLeafRelevance": "high"
                        },
                        {
                            "ConditionBrowseLeafId": "M9708",
                            "ConditionBrowseLeafName": "Hypersensitivity",
                            "ConditionBrowseLeafAsFound": "Sensitive",
                            "ConditionBrowseLeafRelevance": "high"
                        },
                        {
                            "ConditionBrowseLeafId": "M4908",
                            "ConditionBrowseLeafName": "Breast Diseases",
                            "ConditionBrowseLeafRelevance": "low"
                        },
                        {
                            "ConditionBrowseLeafId": "M15364",
                            "ConditionBrowseLeafName": "Skin Diseases",
                            "ConditionBrowseLeafRelevance": "low"
                        },
                        {
                            "ConditionBrowseLeafId": "M9890",
                            "ConditionBrowseLeafName": "Immune System Diseases",
                            "ConditionBrowseLeafRelevance": "low"
                        }
                    ]
                },
                "ConditionBrowseBranchList": {
                    "ConditionBrowseBranch": [
                        {
                            "ConditionBrowseBranchAbbrev": "BC04",
                            "ConditionBrowseBranchName": "Neoplasms"
                        },
                        {
                            "ConditionBrowseBranchAbbrev": "BC17",
                            "ConditionBrowseBranchName": "Skin and Connective Tissue Diseases"
                        },
                        {
                            "ConditionBrowseBranchAbbrev": "All",
                            "ConditionBrowseBranchName": "All Conditions"
                        },
                        {
                            "ConditionBrowseBranchAbbrev": "BC20",
                            "ConditionBrowseBranchName": "Immune System Diseases"
                        }
                    ]
                }
            },
            "InterventionBrowseModule": {
                "InterventionMeshList": {
                    "InterventionMesh": [
                        {
                            "InterventionMeshId": "D000069347",
                            "InterventionMeshTerm": "Erlotinib Hydrochloride"
                        },
                        {
                            "InterventionMeshId": "D000077289",
                            "InterventionMeshTerm": "Letrozole"
                        },
                        {
                            "InterventionMeshId": "D000017273",
                            "InterventionMeshTerm": "Goserelin"
                        }
                    ]
                },
                "InterventionAncestorList": {
                    "InterventionAncestor": [
                        {
                            "InterventionAncestorId": "D000000970",
                            "InterventionAncestorTerm": "Antineoplastic Agents"
                        },
                        {
                            "InterventionAncestorId": "D000047428",
                            "InterventionAncestorTerm": "Protein Kinase Inhibitors"
                        },
                        {
                            "InterventionAncestorId": "D000004791",
                            "InterventionAncestorTerm": "Enzyme Inhibitors"
                        },
                        {
                            "InterventionAncestorId": "D000045504",
                            "InterventionAncestorTerm": "Molecular Mechanisms of Pharmacological Action"
                        },
                        {
                            "InterventionAncestorId": "D000047072",
                            "InterventionAncestorTerm": "Aromatase Inhibitors"
                        },
                        {
                            "InterventionAncestorId": "D000065088",
                            "InterventionAncestorTerm": "Steroid Synthesis Inhibitors"
                        },
                        {
                            "InterventionAncestorId": "D000004965",
                            "InterventionAncestorTerm": "Estrogen Antagonists"
                        },
                        {
                            "InterventionAncestorId": "D000006727",
                            "InterventionAncestorTerm": "Hormone Antagonists"
                        },
                        {
                            "InterventionAncestorId": "D000006730",
                            "InterventionAncestorTerm": "Hormones, Hormone Substitutes, and Hormone Antagonists"
                        },
                        {
                            "InterventionAncestorId": "D000045505",
                            "InterventionAncestorTerm": "Physiological Effects of Drugs"
                        },
                        {
                            "InterventionAncestorId": "D000018931",
                            "InterventionAncestorTerm": "Antineoplastic Agents, Hormonal"
                        }
                    ]
                },
                "InterventionBrowseLeafList": {
                    "InterventionBrowseLeaf": [
                        {
                            "InterventionBrowseLeafId": "M9479",
                            "InterventionBrowseLeafName": "Hormones",
                            "InterventionBrowseLeafRelevance": "low"
                        },
                        {
                            "InterventionBrowseLeafId": "M1743",
                            "InterventionBrowseLeafName": "Letrozole",
                            "InterventionBrowseLeafAsFound": "Extension",
                            "InterventionBrowseLeafRelevance": "high"
                        },
                        {
                            "InterventionBrowseLeafId": "M398",
                            "InterventionBrowseLeafName": "Erlotinib Hydrochloride",
                            "InterventionBrowseLeafAsFound": "Phase 2",
                            "InterventionBrowseLeafRelevance": "high"
                        },
                        {
                            "InterventionBrowseLeafId": "M19258",
                            "InterventionBrowseLeafName": "Goserelin",
                            "InterventionBrowseLeafAsFound": "Chronic Pain",
                            "InterventionBrowseLeafRelevance": "high"
                        },
                        {
                            "InterventionBrowseLeafId": "M25510",
                            "InterventionBrowseLeafName": "Protein Kinase Inhibitors",
                            "InterventionBrowseLeafRelevance": "low"
                        },
                        {
                            "InterventionBrowseLeafId": "M7641",
                            "InterventionBrowseLeafName": "Enzyme Inhibitors",
                            "InterventionBrowseLeafRelevance": "low"
                        },
                        {
                            "InterventionBrowseLeafId": "M25459",
                            "InterventionBrowseLeafName": "Aromatase Inhibitors",
                            "InterventionBrowseLeafRelevance": "low"
                        },
                        {
                            "InterventionBrowseLeafId": "M7806",
                            "InterventionBrowseLeafName": "Estrogens",
                            "InterventionBrowseLeafRelevance": "low"
                        },
                        {
                            "InterventionBrowseLeafId": "M7804",
                            "InterventionBrowseLeafName": "Estrogen Antagonists",
                            "InterventionBrowseLeafRelevance": "low"
                        },
                        {
                            "InterventionBrowseLeafId": "M30173",
                            "InterventionBrowseLeafName": "Estrogen Receptor Antagonists",
                            "InterventionBrowseLeafRelevance": "low"
                        },
                        {
                            "InterventionBrowseLeafId": "M9478",
                            "InterventionBrowseLeafName": "Hormone Antagonists",
                            "InterventionBrowseLeafRelevance": "low"
                        },
                        {
                            "InterventionBrowseLeafId": "M20656",
                            "InterventionBrowseLeafName": "Antineoplastic Agents, Hormonal",
                            "InterventionBrowseLeafRelevance": "low"
                        }
                    ]
                },
                "InterventionBrowseBranchList": {
                    "InterventionBrowseBranch": [
                        {
                            "InterventionBrowseBranchAbbrev": "All",
                            "InterventionBrowseBranchName": "All Drugs and Chemicals"
                        },
                        {
                            "InterventionBrowseBranchAbbrev": "ANeo",
                            "InterventionBrowseBranchName": "Antineoplastic Agents"
                        }
                    ]
                }
            }
        }
    }
}